"Prostatic Hyperplasia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Descriptor ID |
D011470
|
| MeSH Number(s) |
C12.294.565.500
|
| Concept/Terms |
Adenoma, Prostatic- Adenoma, Prostatic
- Adenomas, Prostatic
- Prostatic Adenomas
- Prostatic Adenoma
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Hyperplasia".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Hyperplasia".
This graph shows the total number of publications written about "Prostatic Hyperplasia" by people in this website by year, and whether "Prostatic Hyperplasia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 4 | 0 | 4 |
| 2015 | 5 | 1 | 6 |
| 2016 | 7 | 0 | 7 |
| 2017 | 2 | 0 | 2 |
| 2018 | 2 | 2 | 4 |
| 2019 | 7 | 0 | 7 |
| 2020 | 1 | 0 | 1 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostatic Hyperplasia" by people in Profiles.
-
Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: protocol for a prospective observational study. BMC Urol. 2024 May 21; 24(1):110.
-
Increasing Role of the Advanced Practice Provider in Men's Health Clinics: An Analysis of Medicare and Commercial Claims in the United States. Urol Pract. 2023 07; 10(4):320-325.
-
The 10-item LURN Symptom Index (LURN SI-10) Detects Additional Symptoms and Shows Convergent Validity With the IPSS in Men Presenting With Lower Urinary Tract Symptoms. Urology. 2023 01; 171:184-189.
-
TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat Commun. 2022 04 19; 13(1):2133.
-
Do Minimally Invasive Benign Prostatic Hyperplasia Treatments Preserve Sexual Function? A Contemporary Review of the Literature. Curr Urol Rep. 2021 Nov 02; 22(11):56.
-
Prostate minimally invasive procedures: complications and normal vs. abnormal findings on multiparametric magnetic resonance imaging (mpMRI). Abdom Radiol (NY). 2021 09; 46(9):4388-4400.
-
Prostate MR: pitfalls and benign lesions. Abdom Radiol (NY). 2020 07; 45(7):2154-2164.
-
Characterizing the Benign Prostatic Hyperplasia Literature: A Bibliometric Analysis. Urology. 2020 Feb; 136:202-211.
-
Catheter management after benign transurethral prostate surgery: RAND/UCLA Appropriateness Criteria. Am J Manag Care. 2019 12 01; 25(12):e366-e372.
-
ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. J Am Coll Radiol. 2019 Nov; 16(11S):S378-S383.